CHM.AX closed at $0.06 (-12.31%) on July 1, 2026, after Chimeric Therapeutics announced the appointment of Hawkesbury Partners as an Independent Financial Adviser. * The strategic review aims to identify and evaluate opportunities to maximize shareholder value, as the Board believes the company's current market capitalization does not reflect its embedded value. * Options to be explored include strategic partnerships, funding, licensing, co-development agreements, mergers, asset sales, and alternative capital structures.